Back to Search
RAYMOND HOHL, MD
MD
Hematology & Oncology Physician
NPI: 1710975651IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
28173(IA)MD451620(PA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
RUSH MEDICAL COLLEGE OF RUSH UNIVERSITY
Class of 1984
Research & Publications (20)
Development and characterization of an overtraining animal model.
PMID 19346970·Med Sci Sports Exerc·2009
4-observational
Apparatus for measuring rat body volume: a methodological proposition.
PMID 17082370·J Appl Physiol (1985)·2007
7-preclinical
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
PMID 19646757·Leuk Res·2010
8-other
The intermediate enzymes of isoprenoid metabolism as anticancer targets.
PMID 19519294·Anticancer Agents Med Chem·2009
6-review
Synthesis and biological activity of a fluorescent schweinfurthin analogue.
PMID 19464190·Bioorg Med Chem·2009
8-other
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
PMID 19255312·J Clin Oncol·2009
3-trial
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
PMID 18835038·Leuk Res·2009
5-case
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.
PMID 19373653·Leuk Lymphoma·2009
3-trial
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
PMID 18272914·Ann Oncol·2008
3-trial
Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
PMID 18308574·Bioorg Med Chem·2008
8-other
Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue.
PMID 18457649·Anal Biochem·2008
7-preclinical
Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
PMID 18083912·J Pharmacol Exp Ther·2008
4-observational
Mode I and Mode III fractures in intermediate zone of full-thickness porcine temporomandibular joint discs.
PMID 18228145·Ann Biomed Eng·2008
7-preclinical
Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism.
PMID 18079357·J Pharmacol Exp Ther·2008
4-observational
Imaging as a biomarker for therapy response: cancer as a prototype for the creation of research resources.
PMID 18802422·Clin Pharmacol Ther·2008
8-other
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
PMID 17905588·Bioorg Med Chem·2008
8-other
Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
PMID 17586475·Biochem Pharmacol·2007
8-other
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
PMID 17634483·J Clin Oncol·2007
3-trial
Clinical pharmacology: bridging discovery and practice.
PMID 17505487·Clin Pharmacol Ther·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 500 UNIVERSITY DR
HERSHEY, PA 17033 - Phone
- (800) 243-1455
Quick Facts
- NPI
- 1710975651
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile